20 June 2020: Database Analysis
Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer
Hua Ge 1ABCDEF* , Yan Yan 2BCDE , Maozhao Yan 1CEF , Lingfei Guo 1EF , Kun Mao 1CFDOI: 10.12659/MSM.923208
Med Sci Monit 2020; 26:e923208
Table 3 Correlation of SATB1 mRNA expression and prognosis in breast cancer with different clinicopathological characters by Kaplan-Meier plotter.
| Clinicopathological characteristics | Overall survival (n=1402) | Progression-free survival (n=3955) | ||||
|---|---|---|---|---|---|---|
| N | HR | P-value | N | HR | P-value | |
| Positive | 548 | 0.56 (0.39–0.81) | 0.0015 | 2061 | 0.8 (0.68–0.94) | 0.0062 |
| Negative | 251 | 0.81 (0.51–1.80) | 0.36 | 801 | 0.90 (0.72–1.13) | 0.38 |
| Positive | 83 | 0.38 (0.10–1.54) | 0.16 | 589 | 0.92 (0.65–1.30) | 0.62 |
| Negative | 89 | 0.69 (0.27–1.77) | 0.43 | 549 | 0.89 (0.66–1.19) | 0.42 |
| Positive | 129 | 0.86 (0.43–1.73) | 0.68 | 252 | 0.17 (0.76–1.81) | 0.47 |
| Negative | 130 | 0.85 (0.36–2.01) | 0.71 | 800 | 0.70 (0.54–0.91) | 0.0078 |
| Basal | 241 | 0.70 (0.43–1.14) | 0.15 | 618 | 0.81 (0.63–1.04) | 0.092 |
| Luminal A | 611 | 0.79 (0.55–1.12) | 0.19 | 1933 | 0.93 (0.78–1.10) | 0.39 |
| Luminal B | 433 | 0.71 (0.49–1.03) | 0.071 | 1149 | 0.82 (0.68–0.99) | 0.043 |
| Positive | 313 | 0.85 (0.58–1.25) | 0.4 | 3951 | 0.83 (0.68–1.01) | 0.064 |
| Negative | 594 | 0.83 (0.57–1.20) | 0.31 | 2020 | 0.93 (0.79–1.10) | 0.41 |
| 1 | 161 | 0.57 (0.23–1.40) | 0.21 | 345 | 0.96 (0.57–1.61) | 0.87 |
| 2 | 387 | 0.65 (0.42–1.00) | 0.047 | 901 | 0.88 (0.69–1.12) | 0.29 |
| 3 | 503 | 0.80 (0.58–1.12) | 0.19 | 903 | 0.88 (0.71–1.09) | 0.25 |
| Mutated | 111 | 0.41 (0.18–0.92) | 0.025 | 188 | 0.52 (0.32–0.84) | 0.0071 |
| Wild type | 187 | 0.70 (0.36–1.34) | 0.28 | 273 | 0.98 (0.65–1.50) | 0.94 |
| Basal-like 1 | 58 | 0.55 (0.18–1.70) | 0.29 | 171 | 1.08 (0.67–1.74) | 0.74 |
| Basal-like 2 | 38 | 4.20 (0.89–19.86) | 0.049 | 76 | 0.56 (0.27–1.15) | 0.11 |
| Immunomodulatory | 100 | 0.82 (0.32–2.07) | 0.67 | 203 | 0.65 (0.36–1.19) | 0.16 |
| Mesenchymal | 73 | 0.81 (0.37–1.77) | 0.59 | 177 | 0.78 (0.51–1.20) | 0.26 |
| Luminal androgen receptor | 83 | 0.80 (0.41–1.56) | 0.51 | 203 | 1.13 (0.76–1.70) | 0.54 |
| HR – hazard ratio; ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2. | ||||||